

Appln. No. 09/700,751  
Amdt. dated July 21, 2004  
Supplementing Amendment of January 12, 2004

REMARKS

Claims 10, 12, 15-18, 41, 42 and 44-80 presently appear in this case. The present communication is intended to supplement applicant's amendment of January 12, 2004, so as to clarify in claim 46 that the nucleoside derivative used in the method must be an A3 selective A3RAg. Thus, any chemical compound that falls within the formula of the claim must test positive as being an A3 selective A3RAg before it will fall within the scope of the claim. This property may readily be tested for any given compound within the scope of the claim using the assays disclosed in the present specification.

Applicant hereby acknowledges with gratitude the interview conducted on June 16, 2004, among Examiners Lewis and Barts, the undersigned attorney, the inventor Dr. Pnina Fishman, and a representative of the assignee, Dr. Ilan Cohn. This interview was conducted prior to the time that the examiner had an opportunity to consider applicant's amendment of January 12, 2004. Accordingly, the interview was devoted to explaining the points made in the evidence filed with that response. As the PTO had not yet acknowledged receipt of that response, another copy was left with the examiner, along with a copy of the PTO-stamped postcard, proving its receipt on

Appln. No. 09/700,751  
Amdt. dated July 21, 2004  
Supplementing Amendment of January 12, 2004

January 12, 2004. Applicant notes from Private PAIR that this amendment has been officially captured in the PTO IFW database. Thus, the bulk of the substance of the interview appears in applicant's remarks and applicant's affidavits filed January 12, 2004.

The examiners pointed out in the interview that certain compounds of the references fall within the scope of the formula (I) in claim 46. Applicant explained that, as claim 46 was dependent from claim 45, which was in turn dependent from claim 41, it was still necessary for any compound within the scope of that formula to be an A3 selective adenosine A3 receptor agonist (A3RAg). To further clarify this point, applicant volunteered to amend those dependent claims with general formulae to clarify that the active ingredient still must be an A3 selective A3RAg. The present amendment accomplishes that goal. As to support in the specification for the proposed amendments, reference is made to the paragraph bridging pages 67 and 68 of applicant's amendment of January 12, 2004.

Accordingly, consideration of the present supplemental amendment in conjunction with applicant's amendment of January 12, 2004, and, particularly in light of


Appln. No. 09/700,751  
Amdt. dated July 21, 2004  
Supplementing Amendment of January 12, 2004

the interview, reconsideration and allowance are hereby  
earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By



Roger L. Browdy

Registration No. 25,618

RLB:jab

Telephone No.: (202) 628-5197

Faxsimile No.: (202) 737-3528

G:\BN\COH\COHN\PTO\SuppAmd19JL04VerB.doc

JUL. 21. 2004 6:19PM

BROWDY AND NEIMARK

NO. 4737 P. 43

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office, on the date shown below.

Jonathan Brammer  
Name

J. B.  
Signature

July 21, 2004  
Date